1.67
-4.02%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Alaunos Therapeutics
From its filings with the US Securities and Exchange Commission
Alaunos Therapeutics is based in Fort Lauderdale, Florida and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker TCRT. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $5,000 and a net loss of $4.2m. At that date it held total assets of $3.0m and shareholders' equity of $2.2m.
We are a preclinical-stage biopharmaceutical company focused on the development of novel, orally administered small-molecule therapeutics for obesity and related metabolic disorders, such as metabolic dysfunction-associated steatotic liver disease (MASLD, a type of fatty liver disease). The program aims to develop a differentiated, non-hormonal, non-incretin approach, unlike hormone-based treatments like GLP-1 drugs. On March 2, 2026, we announced positive preclinical proof-of-concept data for ALN1003 from two separate studies using a standard diet-induced obesity (DIO) mouse model in male C57BL/6 mice maintained on a high-fat diet (60% of calories from fat). Highlights from these studies include dose-dependent body weight loss with favorable body composition changes, reductions in liver weight, improvement in liver function biomarkers, and improvement in metabolic biomarkers. Collectively, these findings suggest encouraging metabolic effects of ALN1003 in the DIO model.
We were previously a clinical-stage oncology-focused cell therapy company developing adoptive TCR-T cell therapies.
Quoted from its 10-K, filed 31 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 20 Aug 2004
- Employees
- 1
- Website
- ziopharm.com ↗
- Head office
- 501 E LAS OLAS BLVD, FORT LAUDERDALE, FL, 33301
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. Holger WeisChairman of the Board, Chief Executive Officer, since 2020$132,090
- Ms. Melinda LackeyLegal and Administrative Officer, Corporate Secretary$430,370
- Mr. Ferdinand GroenewaldVice President - Finance$162,304
- Mr. Michael JermanDirector
- Mr. Robert PostmaIndependent Director$83,441
- Mr. Jaime VieserIndependent Director$80,815
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 39
- Environment
- 38
- Social
- 64
- Governance
- 14
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Ad-RTS-IL-12 + veledimex is in Phase II trials for metastatic melanoma and breast cancer.
- ZIOPHARM Oncology has a focused immuno-oncology platform with gene expression control.
- The company employs 103 full-time employees in Boston, Massachusetts.
Weaknesses
- The company has only one employee listed in the facts.
- ZIOPHARM Oncology's IPO was in 2004, which may indicate limited recent growth.
- Ad-RTS-IL-12 + veledimex is still in Phase II clinical trials.
Opportunities
- The immuno-oncology market is expanding with new cancer treatments.
- ZIOPHARM Oncology can leverage its gene delivery system for additional therapies.
- The company can expand into new cancer indications beyond melanoma and breast cancer.
Threats
- Ad-RTS-IL-12 + veledimex faces competition from other immuno-oncology therapies.
- Regulatory approval delays could impact the development timeline.
- The biotechnology sector has high failure rates in clinical trials.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.